IBDEI1AN ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22919,1,4,0)
 ;;=4^682.1
 ;;^UTILITY(U,$J,358.3,22919,1,5,0)
 ;;=5^Cellulitis Of Neck
 ;;^UTILITY(U,$J,358.3,22919,2)
 ;;=^271889
 ;;^UTILITY(U,$J,358.3,22920,0)
 ;;=376.01^^125^1398^10
 ;;^UTILITY(U,$J,358.3,22920,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22920,1,4,0)
 ;;=4^376.01
 ;;^UTILITY(U,$J,358.3,22920,1,5,0)
 ;;=5^Cellulitis Of Orbit
 ;;^UTILITY(U,$J,358.3,22920,2)
 ;;=^259068
 ;;^UTILITY(U,$J,358.3,22921,0)
 ;;=681.10^^125^1398^11
 ;;^UTILITY(U,$J,358.3,22921,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22921,1,4,0)
 ;;=4^681.10
 ;;^UTILITY(U,$J,358.3,22921,1,5,0)
 ;;=5^Cellulitis Of Toe
 ;;^UTILITY(U,$J,358.3,22921,2)
 ;;=^271885
 ;;^UTILITY(U,$J,358.3,22922,0)
 ;;=682.2^^125^1398^12
 ;;^UTILITY(U,$J,358.3,22922,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22922,1,4,0)
 ;;=4^682.2
 ;;^UTILITY(U,$J,358.3,22922,1,5,0)
 ;;=5^Cellulitis Of Trunk
 ;;^UTILITY(U,$J,358.3,22922,2)
 ;;=^271890
 ;;^UTILITY(U,$J,358.3,22923,0)
 ;;=070.1^^125^1398^26
 ;;^UTILITY(U,$J,358.3,22923,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22923,1,4,0)
 ;;=4^070.1
 ;;^UTILITY(U,$J,358.3,22923,1,5,0)
 ;;=5^Hepatitis A 
 ;;^UTILITY(U,$J,358.3,22923,2)
 ;;=^126486
 ;;^UTILITY(U,$J,358.3,22924,0)
 ;;=070.30^^125^1398^27
 ;;^UTILITY(U,$J,358.3,22924,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22924,1,4,0)
 ;;=4^070.30
 ;;^UTILITY(U,$J,358.3,22924,1,5,0)
 ;;=5^Hepatitis B, Acute
 ;;^UTILITY(U,$J,358.3,22924,2)
 ;;=^266626
 ;;^UTILITY(U,$J,358.3,22925,0)
 ;;=070.32^^125^1398^28
 ;;^UTILITY(U,$J,358.3,22925,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22925,1,4,0)
 ;;=4^070.32
 ;;^UTILITY(U,$J,358.3,22925,1,5,0)
 ;;=5^Hepatitis B, Chronic
 ;;^UTILITY(U,$J,358.3,22925,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,22926,0)
 ;;=070.51^^125^1398^29
 ;;^UTILITY(U,$J,358.3,22926,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22926,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,22926,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,22926,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,22927,0)
 ;;=070.54^^125^1398^30
 ;;^UTILITY(U,$J,358.3,22927,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22927,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,22927,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,22927,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,22928,0)
 ;;=571.41^^125^1398^32
 ;;^UTILITY(U,$J,358.3,22928,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22928,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,22928,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,22928,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,22929,0)
 ;;=571.1^^125^1398^33
 ;;^UTILITY(U,$J,358.3,22929,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22929,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,22929,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,22929,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,22930,0)
 ;;=070.59^^125^1398^34
 ;;^UTILITY(U,$J,358.3,22930,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22930,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,22930,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,22930,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,22931,0)
 ;;=V08.^^125^1398^24
 ;;^UTILITY(U,$J,358.3,22931,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22931,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,22931,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,22931,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,22932,0)
 ;;=042.^^125^1398^25
 ;;^UTILITY(U,$J,358.3,22932,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22932,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,22932,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;
 ;;$END ROU IBDEI1AN
